Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A male patient in his late seventies is evaluated in the emergency department for profound weakness, lightheadedness, and multiple episodes of large-volume melena that began 12 hours ago. Four days prior, he was evaluated at an urgent care clinic for a mild exacerbation of chronic obstructive pulmonary disease characterized by increased dyspnea and purulent sputum. At that time, his chronic medications—apixaban, lisinopril, tiotropium, and formoterol—were continued without dosage adjustments. He was additionally prescribed a five-day course of oral prednisone and an empiric oral antimicrobial. On presentation to the emergency department, his blood pressure is 88/54 mmHg and his pulse is 115/min. Laboratory studies reveal a hemoglobin concentration of 7.6 g/dL (down from a baseline of 13.8 g/dL three months ago) and a serum creatinine of 1.2 mg/dL. Which of the following antimicrobials was most likely prescribed during the urgent care visit?

  1. ClarithromycinCevap
  2. B
    Azithromycin
  3. C
    Levofloxacin
  4. D
    Amoxicillin-clavulanate
  5. E
    Doxycycline

Cevap

The correct answer is clarithromycin.
Clarithromycin is a strong dual inhibitor of both the cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) efflux transporter. Apixaban is a direct factor Xa inhibitor that heavily relies on both CYP3A4 for hepatic metabolism and P-gp for biliary and intestinal excretion. When clarithromycin is co-administered with apixaban, the clearance of apixaban is markedly reduced, leading to a profound, rapid increase in plasma drug concentrations. This pharmacokinetic interaction significantly amplifies the systemic anticoagulant effect, directly resulting in the patient's acute, massive gastrointestinal hemorrhage. In standard clinical practice, strong dual CYP3A4 and P-gp inhibitors must be avoided in patients taking full-dose apixaban, or the apixaban dose must be empirically halved.

Adım Adım Çözüm

1
Identify the primary clinical problem and its timeline.
The patient presents with an acute, life-threatening gastrointestinal hemorrhage (melena, shock, hemoglobin drop) four days after adding new medications to a stable regimen.
Establishing the timeline points to an acute drug-drug interaction or adverse drug event as the precipitating cause.
2
Analyze the patient's baseline medications for bleeding risk.
The patient is taking apixaban, a direct oral anticoagulant (DOAC), which inherently carries a risk of bleeding.
DOACs have specific metabolic pathways; recognizing these pathways is necessary to identify potential drug interactions.
3
Determine the metabolic clearance mechanisms for the baseline anticoagulant.
Apixaban is cleared through hepatic metabolism primarily by the cytochrome P450 3A4 (CYP3A4) enzyme and is pumped out of cells into the gut lumen and bile by the P-glycoprotein (P-gp) efflux transporter.
Understanding the pharmacokinetics of apixaban isolates which types of newly added drugs will cause toxicity.
4
Evaluate the added antimicrobials for their ability to alter apixaban clearance.
Among the common medications for a COPD exacerbation, clarithromycin is a potent dual inhibitor of both CYP3A4 and P-gp.
Inhibition of these pathways leads to a massive accumulation of apixaban in the blood, culminating in severe, acute bleeding.

Anahtar Kavram

Pharmacokinetic drug interactions with direct oral anticoagulants (DOACs)
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru